Brief: Lantern Pharma Reports HARMONIC Data Showing LP-300 Progression-Free Survival Benefit Deepens With Treatment Duration In EGFR Exon 21 L858R Lung Cancer
02/06/2026 13:16
BRIEF-Lantern Pharma Reports HARMONIC Data Showing LP-300 Progression-Free Survival Benefit Deepens With Treatment Duration In EGFR Exon 21 L858R Lung Cancer June 2 (Reuters) - Lantern Pharma Inc LTRN.O:
LANTERN PHARMA REPORTS HARMONIC™ DATA SHOWING LP-300 PROGRESSION-FREE SURVIVAL BENEFIT DEEPENS WITH TREATMENT DURATION IN EGFR EXON 21 L858R LUNG CANCER
LANTERN PHARMA - REPORTS LP-300 PFS BENEFIT DEEPENS WITH TREATMENT DURATION IN L858R LUNG CANCER
LANTERN PHARMA - L858R NSCLC PATIENTS REACHED 8.9-MONTH MEDIAN PFS WITH LP-300; DURABLE RESPONSES BEYOND TWO YEARS
LANTERN PHARMA - LP-300 PLUS CHEMO SHOWS NO CLINICALLY MEANINGFUL TOXICITY BEYOND CHEMOTHERAPY
LANTERN PHARMA - OVER 70% OF L858R PATIENTS SHOW TUMOR REDUCTION; 77% CLINICAL BENEFIT RATE
Source text: ID:nBw3CnYbja
Further company coverage: LTRN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Reports HARMONIC Data Showing LP-300 Progression-Free Survival Benefit Deepens With Treatment Duration In EGFR Exon 21 L858R Lung Cancer
Brief: Lantern Pharma Announces Successful Outcome Of FDA Type C Meeting Request For Harmonic Phase 2 Trial of LP-300 In Never-Smokers With NSCLC
Lantern Pharma Q1 net loss narrows on R&D cost cuts
Brief: Lantern Pharma Inc. Announces Up To $9.25 Million Registered Direct Offering With Existing Holders And A Single Institutional Investor
Brief: Lantern Pharma Inc - Schedules Type C FDA Meeting For Harmonic Protocol Amendments